Over two days, 23 and 24 July 2026, the FDA’s Pharmacy Compounding Advisory Committee met to weigh whether seven peptides should be added to the 503A Bulks List, the roster of bulk drug substances U.S. compounding pharmacies are allowed to work with. By the end of the meeting, the committee backed six. One, emideltide, did not get a recommendation.

Anyone who keeps an eye on peptide research will recognise the names on the docket, which include several of the best-known compounds in circulation. Still, much of the public write-up has made the meeting sound broader than it was. What the committee did, and what it did not do, need to be kept separate.

What FDA put in front of the committee

On the FDA meeting page, the agenda lists not only each substance but also the particular use FDA asked the committee to consider for purposes of the compounding question. On 23 July, four substances were discussed:

BPC-157, free base and acetate, evaluated for ulcerative colitis
KPV, free base and acetate, evaluated for wound healing and inflammatory conditions
TB-500, free base and acetate, evaluated for wound healing
MOTs-C, free base and acetate, evaluated for obesity and osteoporosis

On 24 July, three more followed:

Emideltide, also called delta sleep inducing peptide or DSIP, evaluated for opioid withdrawal, chronic insomnia and narcolepsy
Semax, free base and acetate, evaluated for cerebral ischemia, migraine and trigeminal neuralgia
Epitalon, free base and acetate, evaluated for insomnia

Two points need to be said without hedging. To begin with, these are simply the uses FDA reviewed in order to make a compounding-list decision. They are not conclusions about what any of these substances actually do, and nothing in the agenda claims they are effective for the conditions named. Next, FDA opened a public docket for the meeting, FDA-2025-N-6895, and it closed for comments on 22 July 2026.

How the votes shook out

Reports of the meeting have been uneven, largely because the votes were split across two days and some coverage focused only on day one.

Day one

A 24 July article in Pharmaceutical Executive reports the 23 July vote counts as 8 to 6 in favour for BPC-157, KPV, and TB-500, each with one abstention. For MOTs-C, it reports 7 to 5 in favour, with two abstentions. All four therefore received a positive recommendation that day.

The same piece captures the strangeness of the task with a single quoted line from a committee member: “I’m voting on something here, but I don’t know what that something is.”

Day two and the overall result

After both sessions finished, the National Community Pharmacists Association published a summary on 31 July stating the final outcome: the committee recommended BPC-157, KPV, TB-500, MOTs-C, Epitalon, and Semax, and it declined to recommend emideltide.

We have not found a source that lists the individual vote counts for the second day, so no tallies for that session are given here.

What this vote does not do

This is what tends to disappear in headlines. The National Community Pharmacists Association says it plainly: advisory committee recommendations do not bind the agency.

Even if the committee recommends adding a substance, more has to happen before pharmacies can act as if anything changed. First, the Secretary of Health and Human Services must approve any additions to the 503A Bulks List. Then, as the association explains, pharmacies still cannot compound these substances until final rulemaking is completed.

So the recommendation is one stage in a longer track, not a finish line. Until the rule is finalised, the legal situation in the United States stays the same.

Why this is a U.S. story

Precision about jurisdiction matters here, because once these stories circulate, the geography quickly gets smeared.

Section 503A of the Federal Food, Drug, and Cosmetic Act covers pharmacy compounding in the United States. The 503A Bulks List is a U.S. regulatory tool, the advisory committee is a U.S. committee, and final approval, if any, sits with a U.S. cabinet secretary. None of that shifts medicines regulation inside the European Union, where the EMA and national competent authorities run a separate system.

For European laboratories, nothing practical changes because of this vote. Research materials supplied in Europe remain “research use only” regardless of what a U.S. compounding list does or does not include. For readers trying to understand the wider landscape, our overview of the regulatory status of research peptides, our piece on where the research-use-only line sits, and our summary of EU procurement rules are more directly relevant than the U.S. compounding dispute itself.

What to keep an eye on next

Three signals will show whether this story develops.

Start with the docket. Submissions to FDA-2025-N-6895 are public, and in this kind of process the paper trail often tells you more than the headline vote.

Next, look for FDA’s publication of the meeting record. At the time of writing, the meeting page includes the briefing document, the final agenda, the roster, and the questions posed to members. The summary minutes, which should carry the official voting record for both days, were not yet posted.

Finally, watch rulemaking. U.S. compounding practice does not change until that step is finished, and those timelines tend to run in months, not weeks.

Anyone following or writing about this over the next few months will save time by keeping three different things separate: what FDA evaluated, what the committee recommended, and what U.S. law presently allows. So far, only the first two have shifted.

References

FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA. Briefing Document Introduction, Pharmacy Compounding Advisory Committee, July 23-24, 2026. https://www.fda.gov/media/193342/download
National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. 31 July 2026. https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound
Pharmaceutical Executive. FDA Panel Votes to Loosen Restrictions for Four Peptides. 24 July 2026. https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.